Market Overview

Tesaro Shares Tumble After Disappointing Data Results

Related TSRO
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Market Wrap For March 13: Bears Come Out Of Hibernation As Dow Suffers Largest Daily Loss Since February 3

Shares of Tesaro (NASDAQ: TSRO) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints.

BMO Capital Markets analyst Jim Birchenough reported that investors had expected Tesaro's rolapitant to differentiate itself from other treatments for CINV based on nausea benefit which didn't reach statistical significance. Birchenough added that a better dosing schedule and the absence of reactions may not be enough to differentiate from Merck's Emend.

Tesaro closed at $37.70 on Friday.

Posted-In: BMO Capital Markets Jim BirchenoughAnalyst Color Analyst Ratings


Most Popular

Related Articles (TSRO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free